Autologous Chondrocyte Implantation for Focal Articular Cartilage Lesions
Customize your policy alerts
Sign up for Blue Cross Blue Shield - North Dakota Policy 87 alerts
Get alerted when Policy 87 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage of autologous chondrocyte implantation, including matrix-induced ACI, for disabling full-thickness articular cartilage defects of the knee when clinical, anatomic, age or skeletal maturity, biomechanical, and BMI criteria are satisfied. Other joints and indications are considered investigational.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.